Artiva’s AlloNK Secures FDA Fast Track Designation for Refractory Rheumatoid Arthritis; Stock Climbs
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a clinical-stage biotech company, announced on Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its drug candidate, AlloNK, for the treatment of refractory rheumatoid arthritis (RA) in combination with rituximab. The company has identified refractory RA as the primary focus for AlloNK’s development moving forward.
AlloNK is designed to amplify the effectiveness of B-cell-targeting antibodies, such as rituximab, potentially delivering more robust and sustained B-cell depletion. Artiva noted that AlloNK is the first drug candidate in the deep B-cell depletion category to receive this designation and could become the first to progress to a pivotal RA trial, pending FDA feedback expected in the first half of 2026.
To date, more than 20 patients have been treated with AlloNK in combination with monoclonal antibodies across various indications, including refractory rheumatoid arthritis, Sjögren’s disease, systemic lupus erythematosus, lupus nephritis, and systemic sclerosis. Initial safety and translational data are expected by mid-November, with clinical response data from over 15 refractory RA patients anticipated in the first half of 2026.
“We are prioritizing refractory RA as our lead autoimmune indication for AlloNK due to the significant unmet need in this population,” said Fred Aslan, CEO of Artiva. “Despite the availability of numerous approved RA therapies, over 100,000 patients in the U.S. remain treatment-refractory and could benefit from a deep B-cell depleting therapy.”
Artiva’s stock, which closed at $2.77 on Thursday (down 7.97%), has traded between $1.47 and $15.49 over the past year.
About Artiva Biotherapeutics
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers. We aim to develop therapies that patients and physicians can utilize in a community setting. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). We believe the compelling cell killing properties of NK cells, when combined with mAbs for targeting, creates an opportunity to generate potentially transformative therapies.
For more information about Artiva Biotherapeutics please visit www.artivabio.com.
